Key Highlights
- Michael R. McMullen elected to Bristol Myers Squibb’s Board of Directors, effective July 1, 2024.
- McMullen to serve on the Audit Committee.
- Former Agilent CEO brings 20+ years of executive experience.
- McMullen led Agilent’s transformation, tripling its market cap.
Source: Business Wire
Notable Quotes
- “We are pleased to welcome Mr. Michael McMullen to our Board of Directors. Mike’s extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company’s long-term growth profile, progress our pipeline, and prioritize opportunities where we see the highest return for our patients and shareholders.” — Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer at Bristol Myers Squibb
- “Mike is an accomplished global executive whose transformational success is widely acknowledged by investors and industry experts.” — Theodore R. Samuels, Lead Independent Director of the Board of Directors at Bristol Myers Squibb
- “I am pleased to be joining the Board of Bristol Myers Squibb, a company known and respected for its long history of innovation and scientific discovery.” — Michael R. McMullen, Senior Advisor and CEO at Agilent
SoHC's Take
The addition of Michael R. McMullen to Bristol Myers Squibb’s Board of Directors marks a strategic move to bolster the company’s leadership and growth trajectory. McMullen’s extensive experience in transforming Agilent Technologies into a market leader in life sciences and diagnostics demonstrates his capability to drive significant improvements in growth and profitability. His global operational expertise and leadership style are expected to complement Bristol Myers Squibb’s mission of delivering innovative medicines and enhancing shareholder value. This appointment is a clear indicator of the company’s commitment to fortifying its governance structure and focusing on long-term growth and innovation.
